hypoglycemia from semaglutide following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data Can Ozempic (semaglutide) cause hypoglycemia?

This treatment mimics the functions of two key gut hormones, GLP-1 and GIP, and is clinically proven to aid weight loss and enhance metabolic health

The statements made within this website have not been evaluated by the US Food and Drug Administration

ProRx LLC in Exton, PA, is the most heavily sanctioned partner, with two FDA Warning Letters (March 2025 and April 2026), two voluntary sterile-product recalls covering compounded tirzepatide and semaglutide in August 2024 and October 2025, an open FDA 483 from September/October 2025, and an explicit FDA warning of possible seizure or injunction

This has made the peptide relevant to studies of energy balance, nutrient response, and metabolic adaptation